1. Home
  2. STSS vs BDSX Comparison

STSS vs BDSX Comparison

Compare STSS & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sharps Technology Inc.

STSS

Sharps Technology Inc.

HOLD

Current Price

$1.81

Market Cap

68.7M

Sector

Health Care

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

BUY

Current Price

$18.75

Market Cap

122.0M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
STSS
BDSX
Founded
2017
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Precision Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.7M
122.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
STSS
BDSX
Price
$1.81
$18.75
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
315.9K
129.1K
Earning Date
01-01-0001
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$88,499,000.00
Revenue This Year
N/A
$23.35
Revenue Next Year
N/A
$19.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.08
52 Week Low
$0.01
$0.25
52 Week High
$18.23
$17.40

Technical Indicators

Market Signals
Indicator
STSS
BDSX
Relative Strength Index (RSI) 47.70 81.53
Support Level $1.66 $6.33
Resistance Level $2.04 N/A
Average True Range (ATR) 0.13 1.80
MACD 0.03 0.39
Stochastic Oscillator 42.11 97.27

Price Performance

Historical Comparison
STSS
BDSX

About STSS Sharps Technology Inc.

Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: